Duality Biotherapeutics, Inc. operates as a clinical stage company. The company is headquartered in Shanghai, Shanghai and currently employs 191 full-time employees. The company went IPO on 2025-04-15. The firm is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The firm's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The firm's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The firm principally conducts its businesses in domestic and overseas markets.
09606.HK stock price ended at $359 on 星期五, after dropping 1.05%
On the latest trading day Jan 16, 2026, the stock price of 09606.HK fell by 1.05%, dropping from $362.80 to $359.00. During the session, the stock saw a volatility of 3.70%, with prices oscillating between a daily low of $351.80 and a high of $364.80. On the latest trading day, the trading volume for 09606.HK decreased by 546.6K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 689.8K shares were traded, with a market value of approximately $31.6B.